Impact of Nonadherence to Inhaled Corticosteroid/LABA Therapy on COPD Exacerbation Rates and Healthcare Costs in a Commercially Insured US Population
Jill R. Davis, MS, Bingcao Wu, MS, David M. Kern, PhD, Ozgur Tunceli, PhD, Kathleen M. Fox, PhD, John Horton, MS, Randall F. Legg, PharmD, MBA, Frank Trudo, MD, MBA
Chronic obstructive pulmonary disease (COPD) is characterized by declining lung function attributable to a combination of airway obstruction and inflammation.
When an Outcome Is Overdetermined: Nonadherence, Utilization, and the Impetus for Research in COPD
Steven R. Feldman, MD, PhD, Bernard Goffe, MD, Gary Rice, MBA, Matthew Mitchell, PharmD, MBA, FAMCP, Mandeep Kaur, MD, MS, Debbie Robertson, MS, RDN, LDN, Debra Sierka, PharmD, Jeffrey A. Bourret, PharmD, MS, BCPS, FASHP, Tamara S. Evans, PharmD, MPH, BCPS, Alice Gottlieb, MD, PhD
Clinical Characteristics and Unmet Need Among Patients with Atherosclerotic Cardiovascular Disease Stratified by Statin Use
Qing Huang, PhD, MHS, Michael Grabner, PhD, Robert J. Sanchez, PhD, Vincent J. Willey, PharmD, Mark J. Cziraky, PharmD, Swetha R. Palli, MS, Thomas P. Power, MD, FACC, MRCPI
The benefits of statin therapy in reducing cardiovascular (CV) events are immense. In numerous studies, lowering low-density lipoprotein cholesterol (LDL-C) levels with statin therapy has been shown to reduce rates of major adverse CV events, such as myocardial infarction (MI) and stroke.
Using Statin Therapy to Reduce Atherosclerotic Cardiovascular Disease Risk
Rajiv Mallick, PhD, Aditya Raju, MS, BPharm, Chelsey Campbell, PharmD, MBA, Rashad Carlton, PharmD, MSPH, David Wright, MD, Kimberly Boswell, MD, Michael Eaddy, PharmD, PhD
It has been estimated that approximately 24% of adults in the United States have visible varicose veins, and an estimated 6% have evidence of more advanced chronic venous disease (eg, hyperpigmentation or healed or active ulcer).
Important Insights from Real-World Treatment Patterns and Outcomes for Varicose Veins Management
Evaluating Adherence to Dilated Eye Examination Recommendations Among Patients with Diabetes, Combined with Patient and Provider Perspectives
Maxine D. Fisher, PhD, Yamina Rajput, MS, Tao Gu, PhD, Joseph R. Singer, MD, Amanda R. Marshall, BS, Seonyoung Ryu, PharmD, John Barron, PharmD, Catherine MacLean, MD, PhD, Josephine N. Tran, PharmD, MS, Young In Park, DO, Shalin Pandya, DO, Navin John Muliyil, DO, Brandon David Jensen, DO, Kovin Huynh, DO, Quang T. Nguyen, DO, FACP, FACE, FTOS
The Centers for Disease Control and Prevention (CDC) estimates that approximately 29.1 million people in the United States have diagnosed (21 million) or undiagnosed (8.1 million) diabetes mellitus. The overall prevalence of diabetes in the US population is expected to increase as a result of growing rates of obesity and demographic shifts. Furthermore, the CDC estimates that even with a leveling of the incidence of diabetes, the prevalence of diabetes will double in the next 20 years, because of the aging US population. According to the CDC, the estimated total cost of diabetes in the United States in 2012 was $245 billion, including $176 billion for direct medical costs.
Provider and Payer Collaboration Needed to Ensure Adherence to Recommended Eye Examinations in Patients with Diabetes
Factors Associated with Adherence to the HEDIS Quality Measure in Medicaid Patients with Schizophrenia
Marie-Hélène Lafeuille, MA, Christian Frois, PhD, Michel Cloutier, PhD, Mei Sheng Duh, MPH, ScD, Patrick Lefebvre, MA, Jacqueline Pesa, PhD, MPH, Zoe Clancy, PharmD, John Fastenau, RPh, MPH, Mike Durkin, MSc
Schizophrenia is a devastating psychiatric disorder with a global median lifetime prevalence of 4 per 1000 and a lifetime morbidity risk of 7.2 per 1000. The treatment of schizophrenia has been focused on eliminating the symptoms of the disease and has included antipsychotic medications since the 1950s.
Patient Characteristics, Adherence, and a Metric of Organizational Performance in Behavioral Health
Treatment of Chronic Hepatitis C Infection with Sofosbuvir-Based Regimens in a Commercially Insured Patient Population
John Barron, PharmD, Yiqiong Xie, PhD, Sze-jung Wu, PhD, Jeff White, PharmD, Joseph R. Singer, MD, Bernard Tulsi, MSc, Alan Rosenberg, MD
Sofosbuvir was the first direct-acting antiviral drug to be approved by the US Food and Drug Administration (FDA) for the treatment of hepatitis C virus (HCV) infection. The Centers for Disease Control and Prevention estimates that between 2.7 million and 3.9 million people in the United States have chronic hepatitis C.
Evaluating the True Value of High-Cost Therapies for Hepatitis C Infection
Evaluating Outcomes in Patients with Overactive Bladder within an Integrated Healthcare Delivery System Using a Treatment Patterns Analyzer
Daniel B. Ng, PharmD, MBA, Melissa McCart, PharmD, MS, Christopher Klein, BS, Chelsey Campbell, PharmD, MBA, Robert Schoenhaus, PharmD, Todd Berner, MD
The International Continence Society defines overactive bladder (OAB) as the presence of “urinary urgency, usually accompanied by frequency and nocturia, with or without urgency urinary incontinence, in the absence of urinary tract infection (UTI) or other obvious pathology.”
Implications of Big Data Analysis in the Real-World Setting: The Case of Overactive Bladder Treatment
Impact of Pharmacist-Provided Medication Therapy Management on Healthcare Quality and Utilization in Recently Discharged Elderly Patients
Jordan D. Haag, PharmD, RPh, Amanda Z. Davis, PharmD, RPh, Robert W. Hoel, PharmD, RPh, Jeffrey J. Armon, PharmD, RPh, Laura J. Odell, PharmD, RPh, Ross A. Dierkhising, MS, Paul Y. Takahashi, MD
A key measure of the 2010 Affordable Care Act is the improvement of care transitions within the healthcare continuum. Optimal medication utilization is important during these care transitions.
A Systematic Approach to Medication Therapy Management in Elderly Patients with Chronic Diseases Can Improve Outcomes
Thromboembolic Events Associated with Bevacizumab plus Chemotherapy for Patients with Colorectal Cancer: A Meta-Analysis of Randomized Controlled Trials
Abdullah K. Alahmari, BPharm, PhD candidate, Ziyad S. Almalki, BPharm, PhD candidate, Ahmed K. Alahmari,, Medical Student, Jeff J. Guo, BPharm, PhD
Bevacizumab has shown superiority in improving overall survival for patients with cancer, but because of the increased risk for thromboembolic events leads to higher mortality, such superiority may be affected. Here is a examination of the literature for such adverse events.
Better Patient Education Needed Regarding Thromboembolic Events Risk in Patients with Cancer
Page 2 of 11
Results 11 - 20 of 104
Results 11 - 20 of 104